Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Clin Gastroenterol Hepatol. 2022 Jun;20(6):e1416-e1425. doi: 10.1016/j.cgh.2021.08.015. Epub 2021 Aug 14.
BACKGROUND & AIMS: Garcinia cambogia, either alone or with green tea, is commonly promoted for weight loss. Sporadic cases of liver failure from G cambogia have been reported, but its role in liver injury is controversial.
Among 1418 patients enrolled in the Drug-Induced Liver Injury Network (DILIN) from 2004 to 2018, we identified 22 cases (adjudicated with high confidence) of liver injury from G cambogia either alone (n = 5) or in combination with green tea (n = 16) or Ashwagandha (n = 1). Control groups consisted of 57 patients with liver injury from herbal and dietary supplements (HDS) containing green tea without G cambogia and 103 patients from other HDS.
Patients who took G cambogia were between 17 and 54 years, with liver injury arising 13-223 days (median = 51) after the start. One patient died, one required liver transplantation, and 91% were hospitalized. The liver injury was hepatocellular with jaundice. Although the peak values of aminotransferases were significantly higher (2001 ± 1386 U/L) in G cambogia group (P < .018), the median time for improvement in total bilirubin was significantly lower compared with the control groups (10 vs 17 and 13 days; P = .03). The presence of HLA-B∗35:01 allele was significantly higher in the G cambogia containing HDS (55%) compared with patients because of other HDS (19%) (P = .002) and those with acute liver injury from conventional drugs (12%) (P = 2.55 × 10).
The liver injury caused by G cambogia and green tea is clinically indistinguishable. The possible association with HLA-B∗35:01 allele suggests an immune-mediated mechanism of injury.
gov number: NCT00345930.
藤黄果( Garcinia cambogia )单独或与绿茶联合使用时通常被宣传用于减肥。已有散发性的藤黄果导致肝衰竭的病例报告,但它在肝损伤中的作用仍存在争议。
在 2004 年至 2018 年期间,药物性肝损伤网络(Drug-Induced Liver Injury Network,DILIN)纳入的 1418 例患者中,我们鉴定出 22 例(经高可信度判定)单独使用藤黄果(n=5)、与绿茶(n=16)或南非醉茄( Ashwagandha ,n=1)联合使用藤黄果引起的肝损伤病例。对照组由 57 例含绿茶但不含藤黄果的草药和膳食补充剂(Herbal and Dietary Supplements,HDS)所致肝损伤患者和 103 例其他 HDS 所致肝损伤患者组成。
服用藤黄果的患者年龄在 17 至 54 岁之间,肝损伤发生于用药后 13-223 天(中位数=51)。1 例患者死亡,1 例需要肝移植,91%的患者住院。肝损伤为肝细胞性黄疸。尽管藤黄果组的转氨酶峰值显著更高(2001±1386 U/L,P<0.018),但总胆红素改善的中位时间与对照组相比明显更低(10 天 vs 17 天和 13 天;P=0.03)。含藤黄果的 HDS 患者 HLA-B∗35:01 等位基因的阳性率(55%)显著高于因其他 HDS(19%)和因传统药物引起的急性肝损伤患者(12%)(P=0.002 和 2.55×10)。
藤黄果和绿茶引起的肝损伤在临床上难以区分。与 HLA-B∗35:01 等位基因的可能关联提示损伤存在免疫介导机制。
gov 注册号:NCT00345930。